drugset / Trial / NCT02242812

Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension

NCT02242812

Phase 4 Terminated 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective was to show that telmisartan is not inferior to metoprolol succinate in respect of the percentage change from baseline in LVMI(H) after a 6.5 months treatment period. As secondary objectives, the improvement in left ventricular systolic and diastolic function and blood pressure reduction were assessed

Timeline

Start
2003-09
Primary completion
2004-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metoprolol Other / unclassified 95 mg Oral
Subject Telmisartan Other / unclassified 80 mg Oral

Indications